Researcher
Hristo Svilenov
- Keywords:drug development, biopharmaceutics, biotechnology, biochemical characterisation, biophysics, Protein Engineering, Advanced therapy medicinal products, antibody-engineering, Product formulation, biotherapeutics
- Disciplines:Pharmaceutical technology, Biopharmaceuticals, Biopharmaceutics
Affiliations
- Department of Pharmaceutics (Department)
Member
From1 Sep 2021 → 31 Aug 2024
Infrastructure
1 - 1 of 1
Projects
1 - 6 of 6
- Getting picobodies out of their comfort zone - Investigating the in vitro affinity maturation, folding and structure of isolated picobodiesFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- LNP-DECODE: Deciphering the adjuvants activity of lipid nanoparticle-based mRNA vaccines in primary dendritic cellsFrom1 Jan 2024 → TodayFunding: BOF - projects
- Analysis and prevention of protein particle formation – An approach towards safer antibody drugs in the clinicFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Selective photoporation of the nuclear envelope to mimic pathological defects and facilitate intranuclear delivery.From1 Oct 2022 → TodayFunding: BOF - mobility
- Universal antibody scaffolds with drug-like features for straightforward mini-domain graftingFrom1 Feb 2022 → TodayFunding: BOF - projects
Publications
1 - 10 of 25
- Insights into the stabilization of interferon alpha by two surfactants revealed by STD-NMR spectroscopy(2023)
Authors: Hristo Svilenov, Katharina T. Kopp, Alexander P. Golovanov, Gerhard Winter, Matja Zalar
Pages: 404 - 410 - Get what you want : identifying antibodies against pre-defined epitopes on Frizzled receptors(2023)
Authors: Hristo Svilenov
Pages: 2 - 3 - Principles of antibodies with ultralong complementarity-determining regions and picobodies(2023)
Authors: Marcel Fridolin Passon, Stefaan De Smedt, Hristo Svilenov
- Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties(2023)
Authors: Hristo Svilenov, Paolo Arosio, Tim Menzen, Peter Tessier, Pietro Sormanni
- Antibodies gone bad : the molecular mechanism of light chain amyloidosis(2023)
Authors: Ramona M. Absmeier, Georg J. Rottenaicher, Hristo Svilenov, Pamina Kazman, Johannes Buchner
Pages: 1398 - 1419 - Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants(2022)
Authors: Hristo Svilenov, Romina Bester, Julia Sacherl, Ramona Absmeier, Carsten Peters, Ulrike Protzer, Carsten Brockmeyer, Johannes Buchner
- It is never too late for a cocktail : development and analytical characterization of fixed-dose antibody combinations(2022)
Authors: Dennis Krieg, Gerhard Winter, Hristo Svilenov
Pages: 2149 - 2157 - Combining unfolding reversibility studies and molecular dynamics simulations to select aggregation-resistant antibodies(2021)
Authors: Carolin Berner, Tim Menzen, Gerhard Winter, Hristo Svilenov
Pages: 2242 - 2253 - Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein(2021)
Authors: Hristo Svilenov, Julia Sacherl, Alwin Reiter, Lisa S. Wolff, Cho-Chin Cheng, Marcel Stern, Vincent Grass, Martin Feuerherd, Frank-Peter Wachs, Nicole Simonavicius, et al.
- Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design(2021)
Authors: Hristo Svilenov, Julia Sacherl, Ulrike Protzer, Martin Zacharias, Johannes Buchner